IMPassion130: atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naiv...

Press Briefing 1, October 20 - Breast Cancer: LBA1_PR - IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) ESMO 2018 Congress - Munich, Germany - 19 Oct - 23 Oct 2018